CCEL

Cryo-Cell International, Inc.

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Cryo-Cell International, Inc. (CCEL) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (D). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
D
Factor Score 1.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
B+
Factor Score 3.6 / 5.0
Momentum
B+
Factor Score 3.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 243.5
EV / EBITDA 37.8
Rev Growth YoY -0.0%
Gross Margin 64.5%
Price Return 3M 25.5%
Price Return 12M 15.9%
Catalyst Signal 0.00
Market Cap $39.3M
TTM Revenue $31.1M
Price / Sales 1.3
ROE N/A

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 D (1.5) D+ (1.8) B+ (3.6) B+ (3.8) C+ (2.6) C+ (2.7)
2026-11-04 D (1.4) D+ (1.8) B+ (3.7) B (3.3) C+ (2.7) C+ (2.6)
2026-10-28 D (1.5) D+ (1.8) B+ (3.6) B+ (3.5) C+ (2.7) C+ (2.6)
2026-10-21 D+ (1.5) D+ (1.8) B+ (3.6) B- (3.0) C+ (2.6) C+ (2.5)
2026-10-14 D+ (1.5) D+ (1.8) B+ (3.6) B (3.3) C+ (2.6) C+ (2.6)
Page 1 of 3